Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Jul 21, 2021

SELL
$4.26 - $6.5 $563,129 - $859,235
-132,190 Closed
0 $0
Q1 2021

Apr 28, 2021

SELL
$5.03 - $8.8 $3,269 - $5,720
-650 Reduced 0.49%
132,190 $821,000
Q4 2020

Jan 13, 2021

SELL
$4.04 - $5.31 $348,652 - $458,252
-86,300 Reduced 39.38%
132,840 $650,000
Q3 2020

Oct 15, 2020

BUY
$3.64 - $7.76 $145,600 - $310,400
40,000 Added 22.33%
219,140 $923,000
Q2 2020

Jul 28, 2020

SELL
$4.78 - $8.26 $2,868 - $4,956
-600 Reduced 0.33%
179,140 $1.24 Million
Q1 2020

May 05, 2020

BUY
$4.0 - $21.53 $20,160 - $108,511
5,040 Added 2.88%
179,740 $719,000
Q4 2019

Jan 22, 2020

BUY
$13.94 - $24.12 $155,431 - $268,938
11,150 Added 6.82%
174,700 $3.75 Million
Q2 2019

Jul 10, 2019

BUY
$16.27 - $20.51 $2.66 Million - $3.35 Million
163,550 New
163,550 $3.17 Million

Others Institutions Holding AMRN

About AMARIN CORP PLCUK


  • Ticker AMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 403,206,016
  • Market Cap $185M
  • Description
  • Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for r...
More about AMRN
Track This Portfolio

Track Davenport & CO LLC Portfolio

Follow Davenport & CO LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Davenport & CO LLC, based on Form 13F filings with the SEC.

News

Stay updated on Davenport & CO LLC with notifications on news.